Peptide/Protein Ingredients TRIZ Cases

See how modified silk fibroin peptides with segmented functional motifs and localized amino aci

See how a soluble chimeric protein combining CD46, CD55, and CD59 domains enables AAV-mediated

See how liposome-encapsulated polyphosphate nanoparticles mimic platelet dense granules to acti

See how enzyme-impregnated fabrics use proteases and lipases to degrade viral particles, reduci

A peptide amphiphile nanomatrix coating promotes endothelialization while limiting smooth muscle growth to reduce restenosis and late thrombosis.

Perhydrolytic enzyme catalysts generate peroxycarboxylic acids at controlled concentrations for disinfection, bleaching, and cleaning use.

A high-strength alginate shell reinforces biocompatible hydrogel microfibers, enabling woven, tubular, and other 3D tissue structures.

A self-assembled peptide nanomatrix coating helps stents speed endothelialization while limiting thrombosis, inflammation, and restenosis.

Thermostable d-amino acid transferases use sequence-based enzyme variants to retain catalytic activity across wide temperature and pH ranges.

Targeted amino acid changes improve alpha-amylase stability across pH and temperature ranges while reducing Ca2+ dependency in starch processing.

Partial lanthionization in non-aqueous or semi-aqueous media converts cystine bonds while limiting keratin fragility and controlling sulfonic acid groups.

A converted surface layer acts as an etch stop in atomic layer etching, improving selectivity while protecting exposed underlying materials.

A converted surface layer acts as an etch stop in atomic layer etching, protecting the second material while enabling precise removal of the first.

Precharging the current sense start value from the prior cycle cuts ringing-related settling time and improves converter current accuracy.

A rhombus chip layout uses 60° and 120° corners to fit solder balls more efficiently, shrinking package size without new equipment.

Specific SIRT6 mutations improve DNA repair and telomere integrity to suppress senescence and support treatment of age-related diseases.

Spacing insulin into timed partial doses lowers back pressure and occlusion risk while preserving complete delivery over each control cycle.

Spacing partial insulin doses across a control cycle reduces back pressure and pump occlusion risk while maintaining the recommended bolus.

Sensor feedback adjusts roll and infeed positions to keep tapered structures continuous, aligned, and dimensionally accurate.

Timed intervals between insulin pump actuations lower back pressure and occlusion risk while preserving complete dosing over each control cycle.

Real-time sensor feedback adjusts bend and guide rolls to maintain tapered geometry accuracy and join stock edges during forming.

Real-time sensor feedback adjusts roll and infeed positions to maintain tapered diameter control and edge alignment during continuous forming.

IL-6R blockade with sarilumab plus DMARDs improves rheumatoid arthritis symptoms and disease scores when TNF-α antagonists or methotrexate fall short.

BSH activity converts conjugated bile salts into Giardia-inhibiting deconjugated forms, offering an alternative to metronidazole.

Dominant negative PD-1 is built into CAR T-cells to resist tumor immunosuppression, improving infiltration, persistence, and killing in solid tumors.

A co-expressing adenovirus pairs IL-12 delivery with C-met inhibition to restore tumor immunity and limit growth, migration, and recurrence.

Peptides modeled on ELANE cleave CD95 to trigger broad cancer-cell apoptosis while limiting toxicity to normal cells.

Recombinant salmon UK 114 trimers boost innate immunity and cytotoxic antibodies more effectively than goat-derived proteins for malignant tumors.

Anion exchange purification isolates high-purity Glu-plasminogen from plasma fractions while limiting Lys-plasminogen formation and material loss.

High-concentration antibody formulations use antioxidants and rHuPH20 to enable stable subcutaneous dosing in small injection volumes.

Side-chain anchoring of C-terminal Asp and antioxidant cleavage additives reduce teduglutide impurities while improving yield and purification.

Wet silica sol-gel in a cellulose hydrogel stabilizes topical proteins, slows release, and prevents dripping or drying on chronic ulcers.

Recombinant Y3 proteins bind LDNF glycans on T-ALL cells to support early detection and trigger apoptosis beyond conventional chemotherapy.

Site-specific APOBEC1 mutations curb unwanted RNA editing while preserving DNA base editing efficiency and specificity.

Covalently scaffolded bicyclic peptides improve CD137 binding affinity and specificity, helping limit broad immune responses in therapy.

PD-1 T cells are enriched from peripheral blood and screened with autologous APCs to isolate mutation-specific TCRs for personalized cancer therapy.

High-affinity anti-IL-27 antibodies block STAT1/STAT3 signaling, reduce PD-L1 and TIM-3 expression, and strengthen anti-tumor immunity.

Size-selected TGF-β transformed and untransformed cells reduce aggregation in osteoarthritis therapy while improving dosing consistency and handling.

Computationally designed polypeptides bind avβ6 with high affinity to block TGF-β signaling in avβ6-positive tumors and pulmonary fibrosis.

Alternating drug loading with pH-dependent anionic copolymer coating gives oral microgranules uniform, reproducible release in the colon.

Cyclosporin analogues inhibit cyclophilin D to block MPTP opening, preserve mitochondrial function, and limit organ injury.

Novel aryl pladienolides target SF3B1-mutant spliceosomes to induce neoantigens and improve checkpoint blockade response in cancer.

Conservative DLL4 residue substitutions raise affinity across multiple human Notch receptors, enabling broader therapeutic ligand activity.

Site-specific albumin conjugation lets urate oxidase keep uric acid lowering activity while extending half-life and reducing immune response.

Platelet membrane coating, aptamers, and HRP help Prussian blue nanocomposites penetrate tumors, accumulate locally, and boost photothermal therapy.

By replacing the IL2Rα-binding region with an IL-15 segment, this IL-2 heterodimer lowers toxicity while preserving antitumor signaling.

Localized ribosomes on beads or scaffolds boost cell-free protein output, enabling portable continuous protein production with ribosome reuse.

Edited lineage-specific antigens let targeted cancer therapy spare normal hematopoietic cells while preserving antigen function.

CRISPR knockout of GM-CSF in CAR-T cells reduces CRS and neurotoxicity while preserving proliferation and anti-tumor activity.

Preoperative recombinant VWF dosing supports surgical hemostasis in severe von Willebrand disease while avoiding Factor VIII accumulation.

Engineered MUC5AC-binding TCRs suppress endogenous TCR expression to improve shared-antigen targeting across broader cancer patient groups.

Local IL-12 expression plus C-met inhibition in an oncolytic adenovirus restores tumor immunity, limits toxicity, and suppresses growth.

A selective integrin αvβ3-binding peptide targets osteocytes to slow or reverse 3D bone shape change and support cartilage repair.

Controlled multi-stage vacuum drying shortens botulinum toxin processing while limiting active loss and improving product stability.

Combining tumor-lysing oncolytic viruses with PD-1 or CTLA-4 blockade boosts immune activation and helps overcome early tumor resistance.

PDS5A-derived peptides bind MHC class I and II to activate T cells against cancer cells, expanding immune targeting across patient subtypes.

Affinity-tag purification helps individualized CRISPR/Cas complexes reach high purity while reducing cell-derived contamination in B-cell lymphoma use.

Localized IL-2-armed oncolytic viruses generate tumor-infiltrating T cells for adoptive transfer while limiting systemic toxicity.

Recombinant caveolin-1 peptides protect AEC2 cells from apoptosis and raise surfactant protein-C expression to support lung function.

Malt extract with amylases and fructanases improves pre-caecal carbohydrate digestion in horses while lowering acidosis, colic, and laminitis risk.

Engineered pegylated ADI variants alter antibody-binding epitopes to sustain arginine depletion and extend cancer therapy efficacy.

Alanine at 25-120 mM helps solubilize NFL-TBS40-63 peptide and limit fibrils, enabling sterile injectable formulation and filtration.

Bacillus coagulans MTCC 5856 alone or with a multi-enzyme complex reduces gluten content while supporting nutritional utilization.

Combining XBP1, CD138, and CS1 peptides broadens HLA-A binding and T-cell activation to address antigen heterogeneity in cancer therapy.

A 41-SNP genetic risk score improves pre-symptomatic type 1 diabetes stratification and helps identify high-risk individuals early.

Recombinant HO-1 proteins clear free heme in sickle cell disease, reducing oxidative stress, inflammation, anemia, and organ damage.

Sequencing FSCN2 loss-of-function variants helps identify hearing loss risk and guide genotype-based dosing to limit disease progression.

Intermittent controlled-release PTH dosing maintains serum calcium over 24 hours while lowering hypercalcemia risk and injection burden.

Adjusting the teverelix-to-trifluoroacetate ratio to 1:2.4-1:2.8 prevents gel formation and keeps the suspension injectable and bioavailable.

mRNA encoding engineered CFTR bypasses nuclear DNA import and lowers immune response while improving protein stability, activity, and conductivity.

ELANE and CD95-derived peptides trigger cancer-cell apoptosis through CD95 cleavage, broadening efficacy while limiting toxicity to normal cells.

AGM peptides target nucleolin to inhibit viral replication, while CPP fusion and PEGylation improve uptake, stability, and half-life.

TGFβR1 inhibition and BMP4/6/10 agonists restore terminally exhausted T cells, improving response to immune checkpoint blockade.

Covalently attached Formula (I) compounds modulate host immune response to preserve implanted device fidelity and function.

Small molecules suppress tumor PD-L1 and boost T-cell killing, improving anti-tumor response with fewer side effects than antibody blockade.

Protease-resistant IL-23R peptide inhibitors enable oral delivery while blocking IL-23 signaling for intestinal and inflammatory disease treatment.

CRISPR-edited immune cells combine dual antigen receptors with TCR mispairing control to improve tumor targeting and reduce toxicity.

Targeted BCMA and TACI peptides stimulate cytotoxic T cells to improve immune recognition and killing of antigen-expressing cancer cells.

Repeated IgG-inactivating enzyme dosing keeps donor-specific antibodies below a safe threshold to support HSPC engraftment in sensitized subjects.

Anti-CTLA-4 antibodies target regulatory T cells in adenoid cystic carcinoma to overcome immune evasion and improve treatment response.

Tumor-specific promoters and miRNA control help oncolytic HSV replicate in cancer cells while limiting neurotoxicity and off-target effects.

ACE2-rich stem cell supernatant acts as a decoy to block SARS-CoV-2 binding and help prevent infection in healthy people or animals.

Direct protease cleavage of recombinant NGF precursors plus mixed-mode chromatography improves purity, folding, and usable yield from E. coli.

Minigene rAAV vectors fit the oversized USH1B payload into AAV capacity limits while enabling targeted ocular delivery for Usher syndrome.

Combining activating and inhibitory CARs uses LOH-linked allele loss to kill tumor cells while preventing off-tumor damage.

A mini-dose tPA bolus followed by mutant pro-urokinase speeds clot breakdown while limiting fibrinogen loss and bleeding risk.

Novel N-terminal cysteine peptides achieve nanomolar NRP-1 binding to block VEGF-A165 interaction with higher specificity for anti-angiogenic therapy.

IL-10 and MMP9 overexpression in macrophages helps remodel fibrotic scars, reduce inflammation, and recruit pro-restorative monocytes.

AF protein restores epithelial barrier function to reduce lung fluid transfer in acute respiratory failure, addressing ARDS and related edema.

Viral vectors deliver collagen VII and lysyl hydroxylase 3 through the skin to strengthen anchoring fibrils with less invasive EB treatment.

PKM2-driven macrophage repolarization shifts M1/M2 balance to inhibit tumor growth or reduce chronic inflammation, depending on disease context.

Local pH buffering with SNAC and acid-neutralizing agents protects oral peptides from gastric degradation while improving fasted-stomach absorption.

A modified BChE gene delivery approach hydrolyzes acyl ghrelin to overcome inadequate ghrelin inhibition and improve metabolic control.

Targeted Factor IX substitutions and Fc or albumin fusion raise activity and extend half-life, reducing dosing frequency in hemophilia B.

Haptoglobin or AAV gene delivery binds free hemoglobin, lowers oxidative stress, and helps prevent priapism-linked erectile dysfunction.

Separate polymer and drug solutions are mixed just before injection to cut preparation steps while preserving stable extended leuprolide release.

Fixed weight brackets for long-acting growth hormone dosing simplify administration, cut waste, and maintain similar growth outcomes.

Specific SB10 amino acid mutations raise transpositional activity and DNA insertion efficiency for more effective gene transfer and mutagenesis.

Cyclic peptides bind HIF-1α to block HIF-1α/HIF-1β dimerization, disrupting hypoxia-response signaling in cancer-related cells.

Peptide compounds tune heteroaryl and sulfonamide features to selectively inhibit C1s while improving hemolysis control, permeability, and oral exposure.

Recombinant non-oncolytic adenoviruses express BiTEs at the tumor site to overcome rapid clearance and sustain effective local dosing.

Neutrophil-derived polypeptides and CD95-degrading proteases kill cancer cells selectively while limiting toxicity and resistance.

Alkaline-treated ghost nanovesicles remove cytosolic contents to improve size consistency, reduce immune response, and inhibit inflammation.

Cyclic peptides selected by ribosome display bind CTLA-4 and block CD80 interaction, aiming to balance specificity, toxicity, and manufacturability.

Selective ST6Gal-I sialylation on the Fc glycan α1-3 arm boosts anti-inflammatory activity while avoiding complex α1-6 arm control.

Jellyfish collagen enables longer vocal fold medialisation with low immunogenicity, reduced migration, and fewer repeat injections.

A cephalotocin peptide composition targets vasopressin and oxytocin receptors to boost renal water reabsorption and reduce urine output.

Engineered MSCs deliver sustained local Klotho expression at disease sites, improving targeting where systemic protein dosing falls short.

By targeting MISIIR, CAR T cells improve ovarian cancer selectivity while reducing safety risks from antigens shared with normal tissue.

An rAAV vector delivers ASPA to CNS cells early, lowering N-acetylaspartate buildup to slow leukodystrophy progression.

IgG-degrading enzymes such as IdeS and EndoS inactivate anti-CAR antibodies, helping transferred cells survive longer and remain active.

TLR ligand culture media with neurotransmitters or lipids create uniform stem cell phenotypes for more predictable therapy responses.

Hydrochloride C5a peptide analogs selectively activate APCs while avoiding granulocyte-driven inflammation and speeding immune potency.

Interfacial polyelectrolyte spinning and protein-coated fiber weaving improve artificial tendon strength, durability, and tissue repair.

CD39 and CD73 mimics boost extracellular adenosine to limit ischemia-reperfusion injury, organ failure, and lung damage after hemorrhagic shock.

Routine serum uric acid checks identify loss of response during pegylated uricase therapy and help prevent infusion reactions.

HDAC inhibitor and IL-21 culture reprogram effector T cells into persistent, proliferative central memory cells for adoptive cancer therapy.

Bikunin-specific capture plus heavy-chain ligand detection quantifies intact IAIP more accurately for inflammatory disease monitoring.

Engineered CAR monocytes and macrophages improve solid tumor infiltration, recognition, phagocytosis, and cytotoxic killing.

High-affinity peptides block FadA-E-cadherin binding to curb F. nucleatum-driven carcinogenesis and infection without antibiotic resistance.

Combined GIPR antagonism and GLP-1 agonism improves glycemic control, weight reduction, and liver steatosis in metabolic disorders.

Engineered mice restrict light chain diversity so in vivo selection can find heavy chains that pair with one common human light chain.

Specific pH ranges and stabilizing excipients keep liquid bivalirudin ready to use for months under refrigeration while limiting impurities.

A new VEGF222/NF splice isoform reveals a way to target angiogenesis and lymphangiogenesis more precisely than conventional anti-VEGF therapy.

Ionizable lipid nanoparticles improve mRNA delivery and protein expression in donor platelets while maintaining minimal platelet activation.

Peptoid compounds inhibit Ebola viral replication and may support treatment or prevention when Filovirus diagnosis is difficult.

Low, non-uniform microdystrophin expression is addressed with muscle-specific promoters and engineered AAV capsids that favor skeletal muscle over liver.

NMDP hydrogels induce quiescence at physiological temperature, preserving stem cell viability and differentiation potential without DMSO.

Low-specificity cleavage can cause unproductive repair; coupled end-processing enzymes modify DNA ends to favor targeted gene disruption.

Unnatural amino acids enable selective PEG coupling to IL-2, preserving receptor binding while extending in vivo half-life.

A ternary amphiphilic composition forms stable non-lamellar particles through self-assembled liquid crystalline structures.

Synthetic peptides disrupt 14-3-3ε binding to induce apoptosis in squamous cell carcinoma, reducing tumor growth without invasive surgery.

Mutant organophosphorus acid anhydrolase enzymes degrade toxic V-agent chemical compounds through specific amino acid substitutions.

A 3D scaffold recruits and destroys cancer cells to generate tumor antigens in situ.

A biologically active fibrinogen-fibronectin matrix sequesters growth factors on alkyl acrylate polymers to support cell proliferation.

Specific amino acid substitutions in butyrylcholinesterase mutants increase catalytic efficiency against (-)-cocaine, reducing plasma half-life.

Segmented encoder channels detect signal faults to prevent incorrect dosages without excessive complexity.

Block copolymers form polyion complexes with cytokines to extend blood retention time while maintaining in vivo stability and reducing systemic toxicity.

Microbiota-derived proteins stimulate IL-10 secretion from human immune cells, avoiding side effects of high-dose recombinant therapy.